We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Syros Pharmaceuticals Inc | NASDAQ:SYRS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -1.35% | 5.13 | 5.00 | 5.79 | 5.34 | 5.05 | 5.15 | 95,324 | 01:00:00 |
From May 2021 to May 2024
By Stephen Nakrosis
Shares of Syros Pharmaceuticals are trading higher in Wednesday's after-hours market, following the company's announcement the U.S. Food and Drug Administration granted orphan drug designation to tamibarotene to treat myelodysplastic syndrome.
The FDA grants orphan drug status to treatments for rare diseases and the designation qualifies the sponsor of the drug for various development incentives, including tax credits for qualified clinical testing.
At 4:42 p.m. ET, the company's shares were trading 10.36% higher at $2.13 a share.
The stock finished the day's regular-trading session with a 6.76% loss, closing at $1.93 a share.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 02, 2022 17:01 ET (22:01 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Syros Pharmaceuticals Chart |
1 Month Syros Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
